Pipeline Discovery Pre-clinical Studies Phase Ⅰ Studies Phase Ⅱ Studies Phase Ⅲ Studies NDA / BLA Market
TMB-365/TMB-380 (TMB-365 and TMB-380 combination)

TMB-365/TMB-380 (TMB-365 and TMB-380 combination)

Dual Antibody Combination of TMB-365 with TMB-380

 

With broad efficacy over clades of prevalent HIV-1 variants and the long in vivo lifetimes or PK half-life, long acting, of TMB-365 and TMB-380, the dual antibody combination of TMB-365 with TMB-380, like their peers, also dual antibody combination 3BNC117 and 10-1074, are approached for HIV-1 therapy and/or prophylaxis purposes. [1, 2, 3]  The TMB-365 and TMB-380 combination is designated for the treatment of HIV-1 in virologically suppressed patients. [4, 5] 

 

Reference

  1. Cohen YZ et al., “Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.” PLOS ONE (2019)
  2. Julio CC et al., “Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates” J. Virol. (2021) 95: e01909-20
  3. Wagh K et al., “Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection” PLOS Pathogens (2016)
  4. ViiV Healthcare Press and News Release: ViiV Healthcare to Present New Long-term Findings from Its Innovative 2-Drug and Long-Acting HIV Medicines Portfolio at CROI 2022. 07 FEB, 2022
  5. ViiV Healthcare Press and News Release: ViiV Healthcare Announced US FDA Approval of CABENUVA (CABOTEGARVIR, RILPIVIRINE) for Use Every Two Months, Expanding the Label of The First and Only Complete Long Acting HIV Treatment. 01 FEB. 2022